Amended Statement of Ownership (sc 13g/a)
June 11 2020 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange
Act of 1934
(Amendment No. 1)
Menlo
Therapeutics Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
586858 102
(CUSIP Number)
June 9, 2020
(Date of Event which Requires Filing of this
Statement)
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
*
|
The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
|
The information required on
the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
CUSIP No. 586858
102
|
1
|
NAMES OF REPORTING PERSONS
|
|
Vivo
Capital VIII, LLC
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a) ☐
|
(b)
☐
|
3
|
SEC
USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE
OF ORGANIZATION
|
Delaware
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH
|
5
|
SOLE VOTING POWER
|
3,643,824
(1)
|
6
|
SHARED VOTING POWER
|
0
|
7
|
SOLE DISPOSITIVE
POWER
|
3,643,824
(1)
|
8
|
SHARED DISPOSITIVE
POWER
|
0
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
3,643,824
(1)
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
|
☐
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
2.2
% (2)
|
12
|
TYPE
OF REPORTING PERSON (See Instructions)
|
OO
|
|
|
|
|
|
(1)
|
The shares of common stock, par value $0.0001 (the “Common Stock”) of the Issuer are held of record by Vivo Capital
Fund VIII, L.P., and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund
VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.
|
(2)
|
Based on 167,153,043 shares of Common Stock of the Issuer outstanding after the underwritten offering, which includes full
exercise of the underwriters’ over-allotment option, as disclosed in the prospectus supplement filed by the Issuer on June
5, 2020, pursuant to Rule 424(b)(2) under the Securities Act of 1933, which is part of the Issuer’s Registration Statement
on Form S-3 (File No.333-229482) and in the periodic report on Form 8-K, filed by the Issuer on June 9, 2020. .
|
Item 1.
|
(a)
|
Name of Issuer:
|
Menlo Therapeutics
Inc.
|
(b)
|
Address of Issuer's Principal Executive Offices:
|
520 U.S.
Highway 22, Suite 204
Bridgewater,
New Jersey 08807
Item
2.
|
(a)
|
Name
of Person Filing:
|
Vivo
Capital VIII, LLC
|
(b)
|
Address of Principal Business Office or, if None, Residence:
|
192 Lytton
Avenue, Palo Alto, CA 94301
Vivo
Capital VIII, LLC is a Delaware limited liability company.
|
(d)
|
Title of Class of Securities:
|
Common
Stock
586858
102
Item 3.
|
If This Statement is Filed Pursuant to §§
240.13d-1(b), or 240.13d-2(b) or (c),
Check Whether the Person Filing is a:
|
|
(a)
|
☐
|
Broker or dealer registered under
Section 15 of the Act.
|
|
(b)
|
☐
|
Bank as defined in Section 3(a)(6) of the Act.
|
|
(c)
|
☐
|
Insurance company as defined in Section 3(a)(19) of
the Act.
|
|
(d)
|
☐
|
Investment company registered under Section 8 of the
Investment Company Act of 1940.
|
|
(e)
|
☐
|
An investment adviser in accordance with §
240.13d-1(b)(1)(ii)(E);
|
|
(f)
|
☐
|
An employee benefit plan or endowment fund in accordance
with § 240.13d-1(b)(1)(ii)(F);
|
|
(g)
|
☐
|
A parent holding company or control person in accordance
with § 240.13d-1(b)(l)(ii)(G);
|
|
(h)
|
☐
|
A savings association as defined in Section 3(b) of
the Federal Deposit Insurance Act;
|
|
(i)
|
☐
|
A church plan that is excluded from the definition of
an investment company under Section 3(c)(14) of the Investment Company Act;
|
|
(j)
|
☐
|
A non-U.S. institution in accordance with §
240.13d-1(b)(1)(ii)(J);
|
|
(k)
|
☐
|
Group, in accordance with §
240.13d-1(b)(l)(ii)(K).
|
If filing as a non-U.S. institution
in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:
________________
Not Applicable.
(a) Amount
beneficially owned:
3,643,824
(b) Percent
of class:
2.2
%
(c) Number
of shares as to which such person has:
|
(i)
|
Sole
power to vote or to direct the vote: 3,643,824
|
|
(ii)
|
Shared
power to vote or to direct the vote: 0
|
|
(iii)
|
Sole power to dispose or to direct the disposition of: 3,643,824
|
|
(iv)
|
Shared power to dispose of or to direct the disposition of: 0
|
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following ☒
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
Not
Applicable.
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported
on by the Parent Holding Company or Control Person.
|
Not
Applicable.
|
Item 8.
|
Identification and Classification of Members of the Group.
|
Not
applicable.
|
Item 9.
|
Notice of Dissolution of Group.
|
Not
applicable.
By signing
below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities
solely in connection with a nomination under §240.14a11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Vivo Capital VIII, LLC
|
|
|
|
June 11, 2020
|
|
(Date)
|
|
|
|
/s/ Albert Cha
|
|
(Signature)
|
|
|
|
Managing Member
|
|
(Title)
|
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Apr 2023 to Apr 2024